Key facts
- This page summarizes Jason Lettmann's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Oct 2025, 16:01.
Jason Lettmann - 14 Oct 2025 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- ALXO
- Reported as of
- 14 Oct 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Oct 2025, 16:01:06 UTC
- Prior SEC filing
- 18 Sep 2025
- Next SEC filing
- 28 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelly Pinto, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Lettmann filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 16 Oct 2025.
Change
- Previous filing in this sequence was filed on 18 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001688269
Primary reporting owner
Lettmann Jason
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
- Signature
- /s/ Shelly Pinto, by power of attorney
- Signature date
- 16 Oct 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALXO
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +597,500
- Change %
- Price
- $0.000000
- Shares after
- 597,500
- Date
- 14 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 597,500
- Exercise price
- $1.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.